In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest
 
    Enhanced Injection Experience with Pre-Filled Syringe Solutions
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
 
    Advancing GLP-1 Drug Developments with Integrated Solutions
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
 
    Sustainability at the Heart of Aptar Pharma’s Expansion
Publications, Pharmaceutical, Sustainability
 
    Acceptability of Cyltezo® Pen Among Patients and Healthcare Professionals
Publications, Pharmaceutical, Market Insights, Product Solutions
